Telomerase activity in plasma cell dyscrasias

被引:0
作者
D Xu
C Zheng
S Bergenbrant
G Holm
M Björkholm
Q Yi
A Gruber
机构
[1] Karolinska Hospital,Department of Medicine, Division of Hematology
[2] University of Arkansas for Medical Sciences,Myeloma and Transplantation Research Center
来源
British Journal of Cancer | 2001年 / 84卷
关键词
hTERT; multiple myeloma; plasma cells; telomerase;
D O I
暂无
中图分类号
学科分类号
摘要
Activation of telomerase is essential for in vitro cellular immortalization and tumorigenesis. In the present study, we investigated telomerase activation and its implications in plasma cell dyscrasias including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and plasma cell leukaemia (PCL). All 5 patients with MGUS exhibited normal levels of telomerase activity in their plasma cells. Elevated telomerase activity was found in the samples from 21/27 patients with MM and 4/4 with PCL. In addition, 4 myeloma cell lines all expressed high levels of telomerase activity. The expression of telomerase reverse transcriptase (hTERT) and telomerase RNA template (hTER) was positively associated with the levels of telomerase activity in MM/PCL. Tankyrase expression was upregulated, concomitant with the induction of hTERT and activation of telomerase in MM/PCL. The present findings indicate that MGUS cells may not be immortalized and that activation of telomerase plays a role in the malignant transformation from MGUS to MM. © 2001 Cancer Research Campaign
引用
收藏
页码:621 / 625
页数:4
相关论文
共 50 条
  • [41] TERT regulates cell survival independent of telomerase enzymatic activity
    Ying Cao
    He Li
    Siddhartha Deb
    Jun-Ping Liu
    Oncogene, 2002, 21 : 3130 - 3138
  • [42] Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias
    S. G. Thakkar
    C. Isada
    J. Smith
    M. A. Karam
    J. Reed
    J. W. Tomford
    K. Englund
    M. Richmond
    A. Licata
    C. Hatch
    M. A. Hussein
    Medical Oncology, 2006, 23 : 51 - 56
  • [43] The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
    Jasinski, Marcin
    Bilinski, Jaroslaw
    Basak, Grzegorz W.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias
    Thakkar, SG
    Isada, C
    Smith, J
    Karam, MA
    Reed, J
    Tomford, JW
    Englund, K
    Richmond, M
    Licata, A
    Hatch, C
    Hussein, MA
    MEDICAL ONCOLOGY, 2006, 23 (01) : 51 - 56
  • [45] TERT regulates cell survival independent of telomerase enzymatic activity
    Cao, Y
    Li, H
    Deb, S
    Liu, JP
    ONCOGENE, 2002, 21 (20) : 3130 - 3138
  • [46] Analysis of chromosome 12p deletion in plasma cell dyscrasias
    Jiang, Nan
    Qi, Connie
    Yu, Lei
    Ning, Yi
    An, Gang
    Qiu, Luqui
    Chang, Hong
    LEUKEMIA RESEARCH, 2012, 36 (01) : 32 - 36
  • [47] Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees
    Wiernik, Peter H.
    Dutcher, Janice P.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (01) : 26 - 31
  • [48] Telomerase with mutated catalytic motifs has dominant negative effects on telomerase activity and inhibits cell growth
    Rahman, Ruman
    Mo, Ling
    Cui, Wei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 350 (03) : 796 - 802
  • [49] Apigenin decreases cell viability and telomerase activity in human leukemia cell lines
    Jayasooriya, R. G. P. T.
    Kang, Sang-Hyuck
    Kang, Chang-Hee
    Choi, Yung Hyun
    Moon, Dong-Oh
    Hyun, Jin-Won
    Chang, Weon-Young
    Kim, Gi-Young
    FOOD AND CHEMICAL TOXICOLOGY, 2012, 50 (08) : 2605 - 2611
  • [50] An unusual presentation of plasma cell dyscrasias:: Cardiac tamponade due to myelomatous infiltration
    Arat, M
    Ulusoy, V
    Demirer, T
    Uysal, AV
    Özcan, M
    Dinçer, S
    Ilhan, O
    Koç, H
    LEUKEMIA & LYMPHOMA, 2002, 43 (01) : 145 - 148